John Townsend - 14 May 2026 Form 4/A - Amendment Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Reporting relationship: CFO
Issuer ticker: UNCY
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 15 Jun 2026, 17:23:56 UTC
Original report date: 20 May 2026
Prior SEC filing: 30 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ John Townsend

Key filing fact

John Townsend filed Form 4/A - Amendment for Unicycive Therapeutics, Inc. (UNCY) on 15 Jun 2026.

Key facts

This page summarizes John Townsend's Form 4/A - Amendment filing for Unicycive Therapeutics, Inc. (UNCY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 17:23.

Change

Previous filing in this sequence was filed on 30 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001511906 Primary reporting owner

Townsend John

Relationship: CFO
Address: C/O UNICYCIVE THERAPEUTICS, INC., 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Signature: /s/ John Townsend
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UNCY transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +169,500
Change %
Price: $0.000000^*
Shares after: 169,500
Date: 14 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 169,500
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.